Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years

Jonathan Feld, Abigail Belasen, Shyamala C. Navada

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Introduction: Myelodysplastic syndromes (MDS) represent a range of bone marrow disorders, with patients affected by cytopenias and risk of progression to AML. There are limited therapeutic options available for patients, including hypomethylating agents (azacitidine/decitabine), growth factor support, lenalidomide, and allogeneic stem cell transplant. Areas covered: This review provides an overview of the progress made over the past decade for emerging therapies for lower- and higher-risk MDS (MDS-HR). We also cover advances in prognostication, supportive care, and use of allogeneic SCT in MDS. Expert opinion: While there have been no FDA-approved therapies for MDS in the past decade, we anticipate the approval of luspatercept based on results from the MEDALIST trial for patients with lower-risk MDS (MDS-LR) and ringed sideroblasts who have failed or are ineligible for erythropoiesis stimulating agents (ESAs). With growing knowledge of the biologic and molecular mechanisms underlying MDS, it is anticipated that new therapies will be approved in the coming years.

Original languageEnglish
Pages (from-to)465-482
Number of pages18
JournalExpert Review of Anticancer Therapy
Issue number6
StatePublished - 2 Jun 2020


  • Myelodysplastic syndromes
  • erythropoiesis stimulating agents
  • hypomethylating agents
  • lenalidomide
  • targeted therapies


Dive into the research topics of 'Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years'. Together they form a unique fingerprint.

Cite this